|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 65 Hayden Avenue |
Address2 | |
| City | Lexington |
State | MA |
Zip Code | 02421 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 40026226-75
|
||||||||
|
6. House ID# 398750000
|
||||||||
| TYPE OF REPORT | 8. Year | 2010 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Mark T. Battaglini, Esq., Vice President, Government Affairs |
Date | 01/20/2011 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Settlements of patent litagation between innovator drug companies and generic drug companies (S.369 and H.R. 1760)
Comprehensive Reform of Current patent law (H.R. 1260 and S.515)
S.610 Patent Reform Act of 2009 - changes to drug patent litigation issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Battaglini |
Esq |
|
|
Ginette Elise |
Rhodes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Medical Research
Antibiotic Resistance issues
P.L. 111-148 Patient Protection and Affordable Care Act implementation
P.L. 111-152 Health Car and Education Reconcilliation Act of 2010 implementation
H.R. 6331 Generating Antibiotic Incentives Now Act of 2010
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions)
S.11 To restore the application of the 340B drug discount program to orphan drugs with respect to children's hospitals
H.R. 4994 Medicare and Medicaid Extenders Act of 2010; P.L.111-309 (340B provisions)
H.R. 5712 The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286 (340B provisions)
H.R. 759 Food and Drug Administration Globalization Act of 2009
S.882 The Drug and Device Accountability Act of 2009
H.R. 5740 To provide for the mandatory recall of adulterated or misbranded drugs
S.369 Preserve Access to Affordable Generics Act
H.R. 1706 Protecting Consumer Access to Generic Drugs Act
H.R.573 Fair Prescription Drug Competition Act
S.501 Fair Prescription Drug Competition Act
Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148)
Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152)
H.R. 4213 American Jobs and Closing Tax Loopholds Act of 2010
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Battaglini |
Esq. |
|
|
Ginette Elise |
Rhodes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
P.L. 111-148 Patient Protection and Affordable Care Act implementation
P.L. 111-152 Health Care and Education Reconciliation Act of 2010 implementation
S.3677 Financial Services and General Government Appropriations Act, 2011 ("Pay to Delay" Provision)
S.3686 Labor, Health and Human Services, and Education Appropriations Act, 2011 (Infectious Disease Provisions)
H.R. 5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Children's Hospital and "Pay to Delay" Provision)
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions)
H.R. 3082 Continuing Appropriations and Surface Transportation Extensions Act, 2011; PL 111-322
H.J. RES.105, Making further continuation appropriations for fiscal year 2011, and for other purposes; PL 111-317
H.J. RES.101, Making further continuation appropriations for fiscal year 2011, and for other purposes; PL 111-290
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Battaglini |
Esq. |
|
|
Ginette Elise |
Rhodes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
Antibiotic resistance and wounded troops
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Battaglini |
Esq. |
|
|
Ginette Elise |
Rhodes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare Coverage Issues
H.R.574 Medicare Home Infusion Therapy Coverage Act of 2009
S.254 Medicare Home Infusion Therapy Coverage Act of 2009
H.R.3081 Continuing Appropriations Act, 2011 (340B Provisions)
P.L.111-148 Patient Protection and Affordable Care Act implementation
P.L.111-152 Health Care and Education Reconcilliation Act of 2010 implementation
S.11 To restore the application of the 340B drug discount program to orphan drugs with respect to children's hospitals
H.R.5712 Veterans', Seniors', and Children's Health Technical Corrections Act of 2010 (340B Orphan Drug Children's Hospital and "Pay to Delay" Provisions)
S.3677 Financial Services and General Government Appropriations Act, 2011 ("Pay to Delay" Provision)
S.3686 Labor, Healtha nd Human Services, and Education Appropriations Act, 2011 (Infectious Disease Provisions)
H.R.3082 Continuing Appropriations and Surface Transporation Extensions Act, 2011; P.L.111-322
H.J.RES.105 Making further continuation appropriations for fiscal year 2011, and for other purposes; P.L.111-317
H.J.RES.101 Making further continuation appropriations for fiscal year 2011, and for other purposes; P.L.111-290
H.R.4994 Medicare and Medicaid Extenders Act of 2010; P.L. 111-309 (340B provisions)
H.R.5712 The Physicians Payment and Therapy Relief Act of 2010; P.L.111-286 (340B provisions)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Battaglini |
Esq. |
|
|
Ginette Elise |
Rhodes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Medical Research
Prescription Drug/Federal Drug Admin/Center for Disease Control/Health and Human Services Issues
Antibiotic Resistance Issues
H.R.2400 Strategies to Address Antimicrobial Resistance Act (STAAR)
H.R.2937 MRSA Infection Prevention and Patient Protection Act
S.369 Preserve Access to Affordable Generics Act of 2009
H.R. 6331 Generating Antibiotic Incentives Now Act of 2010
S.3686 Labor, Health, and Human Services, and Education Appropriations Act, 2011(Infectious Disease Provisions)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Battaglini |
Esq |
|
|
Ginette Elise |
Rhodes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address | |
||||||
| City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
| City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |